Using low dose naltrexone to treat pain in HIV patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of low dose naltrexone (LDN) on chronic neuropathic pain in patients living with HIV. Given the challenges of treating chronic pain in this population, which often relies on opioids with significant side effects, LDN offers a potential alternative therapy. The study will enroll participants who have a stable HIV viral load and a diagnosis of neuropathic pain, assessing pain relief and overall quality of life. The approach aims to repurpose an existing medication to improve pain management in a vulnerable patient group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-75, male and female
* HIV infection with a viral load of \< 1000 copies/ml for the past 12 months. (That is the viral load below which, according to the 2018 American College of Obstetricians and Gynecologists (ACOG) Committee Opinion, there is no thought of a significant risk of HIV transmission from the mother to the fetus with vaginal delivery. This was thought to be a reasonable cut-off for inclusion in this study.)
* Diagnosis of neuropathic pain (pain that is associated with a lesion or disease involving the somatosensory nervous system, e.g., painful neuropathy, radicular pain, complex regional pain syndrome, nerve-related pain following spine surgery, etc.) using the neuropathic pain screening tool, painDETECT17, as part of the neuropathic pain screen.
* Pain score \> 4/10 on average on the NPRS lasting \> 3 months (chronic pain)
* Capable of informed consent and willing to comply with the study requirements
* Fluent English-speaking

Exclusion Criteria:

* Allergy to naltrexone (not applicable to the control group)
* Current use of any opioids, up to 10 days before the start of the study (not applicable to the control group)
* Pregnant women
* Nursing mothers and women of childbearing potential not using contraception known to be highly effective (not applicable for the control group). Highly effective contraception methods include a combination of any two of the following during the 12-week study period:

  1. Use of oral, injected, or implanted hormonal methods of contraception or;
  2. Placement of an intrauterine device (IUD) or intrauterine system (IUS);
  3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical /vault caps) with spermicidal foam/gel/film/cream/vaginal suppository;
  4. Total abstinence;
  5. Male/female sterilization.
* Bipolar disorder, schizophrenia, poorly controlled anxiety or depression
* Diagnosis of liver disease, e.g. cirrhosis
* Current diagnosis of either chronic kidney disease or acute kidney injury and/or a GFR \<45 at baseline
* Acute viral hepatitis A, B, C
* Patients who self-report as having tested positive for COVID-19 or have been diagnosed with another viral illness within the past ten days.
* Patients with a known or suspected diagnosis of long-term COVID
* Active drug or alcohol use disorder
* People who may require opioid therapy during the duration of the study, e.g. upcoming surgery
* Transportation issues interfering with return study visits (NA for the control group)
* Adults unable to consent
* Prisoners

Where it's running

• Grady Memorial Hospital
  Atlanta, Georgia, United States Recruiting
• Emory Midtown Hospital
  Atlanta, Georgia, United States Recruiting
• Emory University Hospital
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Anne M McKenzie-Brown, MD — Emory University
• Study coordinator: Anne M McKenzie-Brown, MD
• Email: amckenz@emory.edu
• Phone: 404-686-2410

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• aiTBS and rTMS for Chronic Neuropathic Pain: see if brain stimulation helps

  This study tests whether two brain stimulation methods (aiTBS and high-frequency rTMS) can reduce pain in adults with chronic neuropathic pain, compared with sham stimulation.

  Recruiting Hospital Ambroise Paré Paris · Boulogne-Billancourt, Île-de-France Region · NCT07650526

• ICVAX therapeutic DNA vaccine for people living with HIV in Hong Kong

  This trial tests whether the ICVAX DNA vaccine, given with three different delivery devices, is safe and boosts HIV-specific T-cell responses in adults on stable antiretroviral therapy.

  Recruiting Phase 1 Yicura Holding (HK) Limited · Shatin, New Territories · NCT07530198

• MDMA for severe chronic neuropathic pain

  This will try a single oral dose of MDMA combined with psychotherapy to see if it reduces pain and improves function in adults with moderate-to-severe chronic neuropathic pain that hasn't responded to standard medications.

  Recruiting Phase 2 Unity Health Toronto · Toronto, Ontario · NCT07301632

• rTMS over the motor cortex for cancer-related neuropathic pain

  This trial will try high-frequency rTMS over the primary motor cortex to relieve chronic neuropathic pain in adults with cancer who have not responded to standard drug treatments.

  Recruiting Centre Hospitalier Universitaire de Saint Etienne · Saint-Etienne · NCT07187219

• Spinal transforaminal neurostimulation with FAST and MultiWave for refractory chronic neuropathic pain

  This trial will test whether spinal transforaminal neurostimulation using FAST and MultiWave waveforms can reduce long-standing neuropathic peripheral pain in adults whose pain has not responded to other treatments.

  Recruiting Poitiers University Hospital · Poitiers, France · NCT07154056

• Adding lenacapavir to ART to try to shrink hidden HIV reservoirs

  This study will test whether giving lenacapavir in addition to a stable ART regimen can reduce hidden HIV reservoirs in adults who have had undetectable viral loads for at least three years.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06819176

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.